BMS appoints Harman International chief executive
pharmafile | June 24, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | BMS
Bristol-Myers Squibb has appointed Harman’s chief executive Dinesh Paliwal to its Board of directors.
Paliwal will serve as a member of the Committee on directors and Corporate Governance. He is currently the chairman, president and chief executive officer of Harman International Industries, a provider of premium audio and infotainment systems for the automotive, consumer and professional markets, a position he has held since 2008.
He served as Harman’s president and chief executive officer from 2007 to 2008. Prior to joining Harman, he spent 22 years with ABB Group, where he last held the dual role of president, Global Markets and Technologies of ABB Ltd, and chairman and chief executive officer of ABB North America.
While at ABB, Paliwal lived and worked in China for several years where he also served for three years as economic advisor to the governor of Guangdong Province. Paliwal serves on the board of ADT Corporation and has previously served as the chairman of the US National Foreign Trade Council.
“We are very excited to have Dinesh join our Board,” said Lamberto Andreotti, chief executive, Bristol-Myers Squibb. “He is an accomplished leader who has worked in senior positions in Asia, Europe and the United States. I am confident his insights gained from more than 30 years of broad international experience will be of great value to our company.”
James Cornelius, chairman of BMS, added, “Dinesh is an individual with high integrity. He has an impressive track record for driving entrepreneurship and leading edge innovation as well as a sharp focus on growth. We are fortunate to have him join our Board.”
Related Content
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …
Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …
BMS acquires Mirati Therapeutics for $4.8bn
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …
